Pharmerging Market Boosting Due To Increasing Healthcare Expenditure Till 2025: Grand View Research, Inc.

 

The global pharmerging market is expected to reach USD 2,231.9 billion by 2025, according to a new report by Grand View Research, Inc. This market is expected to grow due to increasing geriatric population, increasing disease burden of chronic disorders and increasing healthcare expenditure.

According to the United Nations (UN), the number of people above the age of 60 years are estimated to be 901 million in 2015. This number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0-40.0% of the prescription drug market, and 40.0-50.0% of the OTC drug market.

tier-i-healthcare-market.png

Another driving factor for the pharmerging market is increasing healthcare expenditure. The global healthcare spending is expected to increase from USD 7.83 trillion in 2013 to USD 18.28 trillion in 2040. It has also been estimated that there will an increase of 3.4%, 3.0%, 2.4% in healthcare expenditure in upper middle-level income countries, lower middle-level income countries and in low-income level countries respectively.

The increasing disease burden of chronic diseases in developing countries is boosting the growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.

Browse full research report on Pharmerging Market: www.grandviewresearch.com/industry-analysis/pharmerging-market        

Further key findings from the report suggest:

  • Pharmaceutical segment was the major contributor for the pharmerging market in 2016.
  • Pharmaceutical sector also recorded the fastest growth in the pharmerging industry.
  • Tier I is driving growth in the pharmerging market.
  • India among the Tier II countries is estimated to witness the fastest growth in the pharmerging industry.
  • Brazil was recorded as the major contributor for Tier II countries.
  • Among Tier III countries, Nigeria and Indonesia are estimated to be driving growth.
  • The key players include Sanofi, Pfizer Inc., AstraZeneca, GlaxoSmithKline, F.Hoffmann-La Roche, GE Healthcare, Eli Lilly, Medtronic, Johnson and Johnson, Abbott.
  • The key strategic initiatives include new product launches, acquisitions and mergers, and collaborations.

Browse more reports of this category by Grand View Research: www.grandviewresearch.com/industry/healthcare                                   

Grand View Research has segmented the pharmerging market by product, and region:

Pharmerging Regional Outlook (Revenue, USD Billion; 2014 – 2025)

  • Tier I
    • China
  • Tier II
    • India
    • Brazil
    • Russia
    • South Africa
  • Tier III
    • Argentina
    • Mexico
    • Poland
    • Ukraine
    • Turkey
    • Saudi Arabia
    • Egypt
    • Algeria
    • Nigeria
    • Thailand
    • Indonesia
    • Pakistan
    • Saudi Arabia

Pharmerging Product Outlook (Revenue, USD Billion; 2014 – 2025)

  • Pharmaceutical
    • Patented prescription drugs
    • Generic prescription drug
    • OTC drugs
  • Other healthcare verticals
    • Medical device
    • Clinical diagnostics
    • Other

Access Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-pharmerging-market                                     

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com

 

Advertisements

Women’s Health Market To Experience Lucrative Growth Due To Child Or Early Marriages Till 2025: Grand View Research, Inc.

 

The global women’s health market is expected to reach USD 51.3 billion by 2025, according to a new report by Grand View Research, Inc. Increasing female geriatric population, introduction of various drugs related to women’s health, and favorable government policies are some of the factors expected to drive growth during the forecast period.

us-womens-health-market.png

Women are more prone to certain diseases, such as osteoporosis, osteoarthritis, anemia, menstruation-related disorders, depression, and obesity. Hence, increase in incidence of these conditions is likely to boost the market in the coming years. According to International Osteoporosis Foundation, global prevalence of osteoporosis among women was over 200.0 million in 1990, and this is anticipated to reach 680.0 million in 2050.

Government and various private organizations are working toward improving women’s health across the world, and this is likely to drive growth in the coming years. Reimbursement coverage provided to women is also a key factor driving the market in developed countries. For instance, various coverage plans in the U.S. provide preventive services for women without charging any copayment. These include screening for anemia, hepatitis B, & breast cancer on a routine basis, folic acid supplements for women who are likely to be pregnant, and contraceptive methods, among others.

Browse full research report on Women’s Health Market: www.grandviewresearch.com/industry-analysis/womens-health-market

Further key findings from the report suggest:

  • Presence of a large female geriatric population, which is susceptible to chronic diseases, is expected to boost growth
  • In 2016, postmenopausal osteoporosis accounted for the largest share of the market due to high incidence of osteoporosis in women after menopause, presence of several major players, and cost-effectiveness of this treatment
  • Contraceptive segment is likely to witness fastest growth during the forecast period due to increase in awareness and usage, government initiatives, technological developments, and favorable regulatory scenario. For instance, in June 2017, Agile Therapeutics, Inc. resubmitted an NDA for Twirla, an investigational low-dose combined hormonal contraceptive patch
  • Geographically, North America held the largest share of more than 30% in 2016 due to presence of major market players, high awareness about regular health check-ups for women, coverage for screening, and increased healthcare expenditure
  • Asia Pacific is expected to exhibit fastest growth during the forecast period due to increasing investments by players in the region, rising awareness about women’s health, and initiatives by various governments and private organizations to improve awareness and access to women’s health products
  • Some of the key players operating in the women’s health market are Allergan; Bayer AG; Merck & Co., Inc.; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics; Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb Company; and Ferring B.V.

Browse more reports of this category by Grand View Research: www.grandviewresearch.com/industry/healthcare                                                               

Grand View Research has segmented the global women’s health market on the basis of application and region:

Application of Women’s Health Outlook (Revenue, USD Million, 2014 – 2025)

  • Postmenopausal Osteoporosis
  • Infertility
  • Endometriosis
  • Contraceptives
  • Menopause
  • Polycystic Ovary Syndrome (PCOS)

Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
  • Asia Pacific
    • Japan
    • China
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa

Access Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-womens-health-market                  

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com

 

Life Sciences BPO Market To Experience Lucrative Growth Due To Rising Demand For Contract Manufacturing Of Raw Materials Till 2024: Grand View Research, Inc.

The life sciences BPO market is expected to reach USD 420 billion by 2024, according to a new report by Grand View Research, Inc. The lucrative growth is attributed to the growing demand for contract manufacturing of raw materials, Finished Dosage Forms (FDFs), medical devices, drug discovery services, regulatory services, pre-clinical and clinical trial services, and pharmacovigilance services.

The pharmaceutical and biotech industry invests heavily in the R&D sector to continuously introduce new molecules, devices, and treatments. The different stages of the drug development such as drug discovery, pre-clinical studies, and clinical trials require huge financial, technological, and human resources.

life-science-bpo-market.png
North America life sciences BPO market, by services, 2013 – 2024 (USD Billion)

In order to cater to the growing needs of the industry, the outsourcing vendors are expanding their product and service offerings and they are targeting niche areas for long-term growth and profitability; altogether these trends are expected to boost the life sciences outsourcing market over the forecast period.

Favorable government initiatives such as the introduction of ICD-10 standards, the increasing adoption of Electronic Health Record systems (EHR), and digital health platforms are enabling the rapid growth of the back-end payer and provider BPO services, such as claims management, claims processing, financial and pay roll management, and other administrative services.

The rising geriatric population coupled with the growing prevalence of various chronic diseases is increasing the burden on the healthcare system and also driving the need for new drugs, and devices, which in turn is expected to boost the contract manufacturing and contract research services over the next nine years.

Moreover, the contract sales and marketing services segments are also expected to witness an increase in demand due to the growing sales and marketing activities for the new product launches over the forecast period.

Browse full research report on Life Sciences BPO Market: www.grandviewresearch.com/industry-analysis/life-science-bpo-market   

Further key findings from the report suggest:

  • In 2015, the pharmaceutical outsourcing segment accounted for the largest revenue share, mainly on account of the growing demand for API and finished dosage form manufacturing services. Moreover, the increasing demand for early stage pre-clinical studies, clinical trials, post-marketing surveillance, and regulatory services are also expected to further drive the market over the forecast period.
  • The services segment including healthcare payer and provider BPO services is expected to emerge as the fastest growing services type with a CAGR of 9.3% over the forecast period
  • In the medical devices contract research outsourcing segment, the product design and development category accounted for nearly 29% in 2015. By 2024, the product implementation services are expected to emerge as the fastest growing category with a CAGR of 13.1% from 2016 to 2024.
  • North America was the largest regional market in 2015. The presence of several major pharmaceuticals, medical device, health insurance, contract research and contract manufacturing (CRAMS) players in this region are amongst the key factors responsible for the region’s large market share. The increasing geriatric population, the growing disease prevalence rates, the shift from ICD 9 to ICD 10 codes are significantly driving the healthcare expenditures and the need for efficient data management, as well as operational costs; therefore, these factors are expected to positively reinforce the life sciences outsourcing market over the forecast period.
  • Asia Pacific is expected to grow at a CAGR of11% over the forecast period. The increase in the number of U.S. FDA manufacturing sites in this region, especially China and India, the growing healthcare burden, patent expiration of several key drugs are expected to significantly boost the life sciences outsourcing market in this region.
  • Furthermore, favorable government initiatives to encourage the use of generic drugs, subsidies for the manufacturing of electronic components and devices, and several tax benefits to promote the export of life sciences services from this region are anticipated to further propel the market growth over the forecast period.
  • Some key market players include Infosys Limited, Lonza Group, PAREXEL International Corporation, Covance, Inc., International Business Machines Corporation. Genpact Limited, Catalent, Inc., ICON plc, Boehringer Ingelheim GmbH, Accenture plc, Quintiles Transnational Corporation, and Anthelio Healthcare Solutions

Browse more reports of this category by Grand View Research: www.grandviewresearch.com/industry/healthcare                                                            

Grand View Research has segmented the life sciences BPO market by service and region:

Life Sciences BPO Services Outlook (Market revenue in USD Billion, 2013 – 2024)

  • Pharmaceutical outsourcing
    • Contract Manufacturing Market
      • API
      • Finished Dose Form
      • Packaging
    • Contract Research Organizations
      • Drug Discovery
      • Pre-clinical Studies
      • Clinical Trial Studies
      • Regulatory Services
      • Pharmacovigilance
    • Medical devices outsourcing
      • Contract Manufacturing Market
        • Electronic Manufacturing Services
        • Finished Goods
        • Raw Materials/ Components
      • Contract Research Organizations
        • Regulatory Consulting Services
        • Product Design and Development Services
        • Product Testing Services
        • Product Implementation Services
        • Product Upgrade Services
        • Product Maintenance Services
      • Contract sales and marketing outsourcing
    • Others

Life Sciences BPO Regional Outlook, (Market Revenue in USD Billion, 2013 – 2024)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • South Africa

Access Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-life-sciences-bpo-market              

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com

Acute Lymphocytic Leukemia Therapeutics Market Is Projected To Grow Rapidly Due To Rising Incidences Of Acute Lymphoblastic Leukemia Till 2025: Grand View Research, Inc.

The global acute lymphocytic/lymphoblastic leukemia therapeutics market is expected to reach USD 3.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.

us-acute-lymphoblastic-leukemia-therapeutics-market.png

Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.

Browse full research report on Acute Lymphocytic Leukemia Therapeutics Market: www.grandviewresearch.com/industry-analysis/acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market                                                

Further key findings from the report suggest:

  • Chemotherapy dominated the market in 2016 owing to its high prescription rate, presence of a wide product portfolio, and easy availability of products
  • Targeted therapy is anticipated to be the most preferred therapy in comparison to other types of therapies due to its associated benefits such as target-specific action and its ability to prevent collateral damage, leading to faster recovery
  • Precursor B-ALL dominated the market in 2016 and is expected to be the fastest growing segment during the forecast period due to increasing prevalence of BCR-ABL and Burkitt leukemia, which are its subtypes
  • North America dominated the market in 2016 owing to factors such as the increase in demand for chemotherapy regimen such as CALGB 8811 and oncaspar in this region
  • Asia Pacific is anticipated to be the fastest growing region with a lucrative CAGR during the forecast period due to growing awareness about ALL. Furthermore, the rising disposable income and presence of large population base are some of the factors expected to propel the growth in this region
  • Key players in this industry are Erytech Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a., and Genzyme Corporation
  • Key players are focusing on strategies such as expansion of product portfolio and collaborations. For instance, in June 2017, Bristol-Myers Squibb Company and QIAGEN entered into an agreement to use Next-Generation Sequencing (NGS) technology to develop gene expression profiles for immune-oncology therapies

Browse more reports of this category by Grand View Research: www.grandviewresearch.com/industry/healthcare                                       

Grand View Research has segmented the global acute Lymphocytic/Lymphoblastic leukemia therapeutics market on the basis of therapy, type, and region:

Therapy Outlook (Revenue, USD Million; 2014 – 2025)

  • Chemotherapy
    • Hyper-CVAD
    • CALGB 8811 regimen
    • Linker regimen
    • Nucleoside Metabolic Inhibitors
    • Oncaspar
  • Targeted therapy
  • Radiation Therapy
  • Stem cell transplantation

Type Outlook (Revenue, USD Million; 2014 – 2025)

  • Philadelphia chromosome
  • Precursor B-cell ALL
  • T-cell ALL

Regional Outlook (Revenue, USD Million; 2014 – 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa

Access Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com

Healthcare Staffing Market Size Is Estimated To Reach $43.6 Billion By 2025: Grand View Research, Inc.

 

The global healthcare staffing market is expected to reach USD 43.6 billion by 2025, according to a new report by Grand View Research, Inc. Rising geriatric population has increased the demand for healthcare services around the globe. However, there is a shortage of efficient nurses and other healthcare professionals.

Shortage of physicians in the coming years is likely to boost the demand for healthcare staffing market in developed regions over the forecast period. For instance, Association of American Medical Colleges had predicted in 2010 that the U.S. is anticipated to face a shortage of 150,000 doctors over the next 10 to 15 years. Furthermore, availability of skilled professionals at lower costs as and when required is anticipated to propel the market growth in the coming years.

us-healthcare-staffing-market.png

Furthermore, in response to the pressure of costs, hospitals are forced to reduce their staff and have implemented policies to ensure that nurses would be available for work when the workload increases. The staffing market has sufficient penetration and can easily provide staff during emergencies.

Flexible schedules, short-term assignments, travel opportunities, and clinical experience at various locations are some of the reasons owing to which healthcare staff prefers to work as locum tenens or travel nurses. Thus, increasing preference of staff to work temporary is anticipated to further boost the market growth.

Browse full research report on Healthcare Staffing Market: www.grandviewresearch.com/industry-analysis/healthcare-staffing-market                                         

Further key findings from the report suggest:

  • Shortage of healthcare staff and rise in demand of healthcare services are expected to propel market growth with a CAGR of 5.4% from 2017 to 2025
  • The allied healthcare segment accounted for the largest share of the market in 2016. It includes physical therapists, medical technologists, occupational therapists, respiratory therapists, pharmacists, and phlebotomists. This can be attributed to higher demand and increase in geriatric population
  • The locum tenens segment is expected to witness the fastest growth during the forecast period. This can be attributed to cost-effectiveness for employers and an increase in the number of physicians choosing to work as locum tenens due to short-term assignments, flexible schedules, and varied clinical experience
  • Geographically, North America was the largest market for healthcare staffing in 2016. Furthermore, it is anticipated to maintain its dominance during the forecast period due to increase in geriatric population, lack of skilled professionals as compared to demand, and local presence of several market players.
  • Asia Pacific is projected to witness the fastest growth during the next decade due to increase in investments by several market players, positive economic outlook, and increasing awareness about contract staffing.
  • Some of the key players are Envision Healthcare Corporation; AMN Healthcare; CHG Management, Inc.; Maxim Healthcare Services, Inc.; Cross Country Healthcare, Inc.; inVentiv Health; Almost Family; TeamHealth; and Adecco Group.

Browse more reports of this category by Grand View Research: www.grandviewresearch.com/industry/healthcare                                    

Grand View Research has segmented the global healthcare staffing market on the basis of service and region:

Service Outlook (Revenue, USD Million, 2014 – 2025)

  • Travel Nurse
  • Per Diem Nurse
  • Locum Tenens
  • Allied Healthcare

Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
  • Asia Pacific
    • Japan
    • China
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa

Access Press Release By Grand View Research:  www.grandviewresearch.com/press-release/global-healthcare-staffing-market                                                       

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com

 

Atrial Fibrillation Market Is Projected To Reach $13.2% from 2014 to 2020: Grand View Research, Inc.

The global atrial fibrillation market is expected to reach USD 16.17 billion by 2020. Rising occurrence of strokes, brain damage and atrial fibrillation owing to blood clots along with an increasing geriatric population is expected to drive industry growth. Technological advancements in the field of microwave catheter ablation and radiofrequency along with rising occurrence of diseases caused by lifestyle habits such as drinking and smoking are further expected to fuel growth. Moreover, increasing demand for smaller cardiac incisions, minimally invasive procedures and small recovery time post-surgery are projected to bolster growth. Also, global aging population combined with the changes in lifestyle increasing the risks of obesity and high blood pressure is likely to drive demand.

Pharmacological products accounted for over 50% market share in 2013. Low prices of these products along with increasing use of anti-coagulants as an add-on therapy to non-pharmacological procedures are expected to drive demand.

Browse full research report on Atrial Fibrillation Market: https://www.grandviewresearch.com/industry-analysis/atrial-fibrillation-treatment-industry

North America accounted for over 40% of global revenue in 2013. High penetration of non-pharmacological procedure and sophisticated reimbursement frameworks has resulted in its substantial demand over the past few years. High patient awareness and healthcare expenditure levels also contributed significantly towards region growth.

Asia-Pacific is expected to witness substantial growth during the forecast period, growing at a CAGR of over 13% from 2015 to 2022. Rising demand for non-pharmacological treatments due to improvement in healthcare infrastructure, high disposable incomes, and growing patient awareness are a few factors accounting for its rapid growth.

Radiofrequency catheter ablation procedure segment is expected to be the fastest growing segment with a CAGR of over 12% over the forecast period. Technological advancements related to maneuverability which helps in making tight bends inside the heart, the optimal size of the lesion produced and lower time required to recover from of catheter ablation is expected to drive demand over the next seven years.

Maze surgery occupied the second largest share of non-pharmacological treatment market. It removes the need for life-long anti-coagulants based treatment while reducing the occurrence of strokes. Anti-coagulants held the dominant market share in pharmacological treatment market as it reduced the incidence of blood clots and strokes which in turn is likely to propel demand over the projected period.

Key industry players include Boston Scientific Corporation, St. Jude Medical Inc., Johnson & Johnson Ltd., Sanofi-Aventis, CardioFocus Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Corporation, Biosense Webster Inc., AtriCure Inc. and Endoscopic Technologies Inc. St. Jude Medical Inc. developed an Endosense’sTactiCath. The technology provides live feedback related to pressure applied during microwave catheter ablations and radiofrequency

Browse more reports of this category by Grand View Research: https://www.grandviewresearch.com/industry/healthcare

Grand View Research has segmented the global atrial fibrillation market on the basis of fields of procedures and region:

Atrial Fibrillation Procedures Outlook

  • Pharmacological Products
  • Anti-arrhythmic Drugs
  • Anti-coagulant Drugs
  • Non-Pharmacological Treatment
  • Catheter Ablation Procedures
  • Radiofrequency
  • HIFU
  • Cryoablation
  • Microwave
  • Laser
  • Maze Surgery
  • Electric Cardioversion

Atrial Fibrillation Regional Outlook

  • North America
  • Europe
  • Asia Pacific
  • RoW

Access Press Release By Grand View Research: https://www.grandviewresearch.com/press-release/global-atrial-fibrillation-market

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: http://www.grandviewresearch.com

Peripheral Vascular Devices Market Is Projected To Grow Rapidly Due To Rising Global Prevalence Of Venous Diseases Or CVI Till 2020: Grand View Research, Inc.

The global peripheral vascular devices market is expected to reach USD 8,918.8 million by 2020, growing at an estimated CAGR of 7.2% from 2014 to 2020, according to a new study by Grand View Research, Inc. Peripheral vascular devices such as IVC filters, angiography catheters and plague modification devices are used for treating peripheral arterial or coronary arterial diseases caused due to the formation of atherosclerotic plaques in arteries. These devices are used to decrease the interference of patients with minimum disturbance during the surgical procedure.

Increasing global geriatric population base triggering incidence rates of target diseases, extensive presence of both private and public external funding programs, changing lifestyle and eating habits are expected to be key driving factors for this market over the next six years. In addition, presence of untapped growth opportunities in emerging markets such as India, Brazil and China and increasing health awareness are also expected to serve this market as future growth opportunities.

Peripheral Vascular Devices Market, by Product, 2013

 

peripheral-vascular-devices-market

Browse full research report on Peripheral Vascular Devices Market: http://www.grandviewresearch.com/industry-analysis/peripheral-vascular-devices-market           

Further key findings from the report suggest:

  • Peripheral vascular stents dominated the peripheral vascular devices market in terms of share at over 30.8% in 2013; driven by increasing demand for drug eluting and bio-absorbable stents. Moreover, the ability of these devices to significantly reduce re-stenosis rates is expected to boost product demand.
  • Embolic protection devices market is expected to grow at the fastest CAGR of 9.2% during the forecast period; owing to increasing demand for minimally invasive endovascular surgical method for removing atherosclerosis from large blood vessels.
  • North America was the largest regional market in 2013, accounting for 40.3% of the global revenue. Presence of sophisticated healthcare infrastructure, high patient awareness levels, healthcare expenditure and high R&D pertaining to drug discovery and development are some of the factors accounting for its large share.
  • Asia Pacific peripheral vascular devices market is expected to grow at the fastest CAGR of 10.0% from 2014 to 2020; primarily owing to the wide presence of unmet medical needs coupled with rapidly improving healthcare infrastructure in emerging markets of India and China.
  • Key industry participants of this market include Abbott Laboratories, Angioscore Inc., Edward Lifesciences Corporation, Medtronic Inc., St. Jude Medical, Teleflex Medical, Volcano Corporation, Boston Scientific Corporation, Teleflex Medical, Cook Group Inc., Cordis Corporation, Covidien, W.L.Gore and Associates Ltd. and Angioscore Ltd.

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/healthcare       

Grand View Research has segmented the peripheral vascular devices market on the basis of product and region:

Peripheral Vascular Devices Product Outlook

  • Peripheral Vascular Stents
  • Peripheral Transluminal Angioplasty Balloon Catheters
  • PTA Guidewires
  • Atherectomy Devices
  • Chronic Total Occlusion Devices
  • Aortic Stents
  • Synthetic Surgical Grafts
  • Embolic Protection Devices
  • Inferior Vena Cava Filters

Peripheral Vascular Devices Regional Outlook

  • North America
  • Europe
  • Asia Pacific
  • RoW

Access Press Release By Grand View Research: http://www.grandviewresearch.com/press-release/global-peripheral-vascular-devices-market      

About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: http://www.grandviewresearch.com